To see all protocols that comply with the WHO Essential Medicine List 

The CLL indication was removed from this multi indication protocol so the correct dose of rituximab from cycle 2 could be given, see ID 3811 Chronic lymphocytic leukaemia bendamustine and rituximab for further information.

Patients with lymphoma should be considered for inclusion into clinical trials. Link to ALLG websiteANZCTR website and Lymphoma Australia website.

Some indications in this protocol are based on limited evidence; please refer to the individual evidence sections for more information.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3794

23 Sep 2021